- Sarepta Therapeutics Announces Positive Vote at US FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy | Sarepta Therapeutics, Inc.Investor Relations | Sarepta Therapeutics, Inc.
- FDA Duchenne Muscular Dystrophy Gene Therapy: ShotsNPR
- Sarepta Gene Therapy FDA Advisory Panel Follow-UpSTAT
- FDA advisers narrowly vote in favor of Sarepta’s DMD gene therapyFierceBiotech
- For patients with Sarepta and muscular dystrophy, Friday’s FDA hearing was crucialBarrons
- See full coverage on Google News